- DKK13.54bn
- DKK11.39bn
- DKK6.24bn
Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover (updated)
Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover
Bavarian Nordic jumps after media report on potential bid
Brief: Bavarian Nordic Confirms Discussion On Potential Takeover
Brief: Bavarian Nordic Gets Acceptance From Health Canada For Review Of New Drug Submission For Chikungunya Vaccine
Brief: Bavarian Nordic Enters Smallpox/Mpox Vaccine Supply Contract With European Country
Valneva rises on vaccines distribution deal in Germany
Brief: Bavarian Nordic Starts Clinical Trials Of Mpox Vaccine In Infants, Pregnant Women
Brief: Bavarian Nordic Announces Sale Of Priority Review Voucher For $160 Mln
Brief: Bavarian Nordic Announces Sale Of Priority Review Voucher For USD 160 Million
Brief: Bavarian Nordic Starts Phase 3 Study Of Chikungunya Vaccine In Children
US CDC accepts recommendations for chikungunya vaccines (updated)
US CDC approves recommendations for chikungunya vaccines
Bavarian Nordic tops STOXX after Q1 revenue beat
Brief: Bavarian Nordic Maintains 2025 Outlook
Kennedy aide and vaccine critic questions recent expert recommendations
Kennedy aide and vaccine critic questions recent expert recommendations
Brief: Bavarian Nordic Wins Contract Options In US For Freeze-dried Smallpox/Mpox Vaccines
Brief: Bavarian Nordic Receives Authorization For Chikungunya Vaccine In UK